1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Lincoln Pharmaceuticals Limited

Lincoln Pharmaceuticals Limited

LINCOLN.NS
Lincoln Pharmaceuticals LimitedIN flagNational Stock Exchange of India
619.65
INR
+5.05
- -
12.41BMarket Cap

Total Valuation

Lincoln Pharmaceuticals Limited carries a market capitalization of 12.41B, placing it among publicly traded companies globally. Its enterprise value stands at 8.94B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap12.41B
Enterprise Value8.94B

Share Statistics

Lincoln Pharmaceuticals Limited currently has 20.03M shares outstanding.

Shares Outstanding20.03M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

Lincoln Pharmaceuticals Limited trades at a trailing price-to-earnings ratio of 12.87. The price-to-sales ratio is 1.69, and the price-to-book ratio stands at 56.48.

PE Ratio12.87
PS Ratio1.69
PB Ratio56.48
P/TBV Ratio1.50
P/FCF RatioN/A
P/OCF RatioN/A

Enterprise Valuation

On an enterprise value basis, Lincoln Pharmaceuticals Limited trades at an EV/EBITDA multiple of 10.75 and an EV/FCF ratio of 1,160.74. The EV/Sales ratio of 1.33 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 10.75 provides insight into valuation relative to core operating earnings.

EV / Sales1.33
EV / EBITDA10.75
EV / EBIT10.75
EV / FCF1,160.74

Financial Position

Lincoln Pharmaceuticals Limited maintains a current ratio of 5.25, meaning it holds 5.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.58, indicating moderate leverage, while an interest coverage ratio of 82.12 demonstrates strong ability to service its debt obligations.

Current Ratio5.25
Quick Ratio2.18
Debt / Equity0.58
Debt / EBITDA0.05
Interest Coverage82.12

Financial Efficiency

Lincoln Pharmaceuticals Limited posts a return on equity of 438.82 and a return on invested capital of 8.82.

Return on Equity (ROE)438.82
Return on Assets (ROA)10.42
Return on Invested Capital (ROIC)8.82
Return on Capital Employed (ROCE)398.66
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover3.92

Taxes

Over the trailing twelve months, Lincoln Pharmaceuticals Limited has paid 277.31M in income taxes, reflecting an effective tax rate of 23.98.

Income Tax277.31M
Effective Tax Rate23.98

Stock Price Statistics

Lincoln Pharmaceuticals Limited's stock has gained approximately 8.92072% over the past 52 weeks. The 50-day moving average sits at 652.18, while the 200-day moving average is 565.58.

Beta (5Y)N/A
52-Week Price Change8.92072%
50-Day Moving Average652.18
200-Day Moving Average565.58
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Lincoln Pharmaceuticals Limited generated 6.71B in revenue and converted that into 878.94M in net income, yielding earnings per share of 43.89. EBITDA reached 831.84M, while operating income came in at 831.84M.

Revenue6.71B
Gross Profit3.60B
Operating Income831.84M
Pretax Income1.16B
Net Income878.94M
EBITDA831.84M
EBIT831.84M
Earnings Per Share (EPS)43.89

Balance Sheet

Lincoln Pharmaceuticals Limited holds 2.42B in cash and equivalents against 44.22M in total debt, resulting in a net debt position of -171.06M. Total book value stands at 200.30M, with working capital of 4.72B providing operational flexibility.

Cash & Cash Equivalents2.42B
Total Debt44.22M
Net Debt-171.06M
Equity (Book Value)200.30M
Book Value Per Share10.00
Working Capital4.72B

Margins

Lincoln Pharmaceuticals Limited operates with a gross margin of 53.63, reflecting its pricing power and cost economics. The operating margin of 12.40 and net profit margin of 13.10 provide insight into operational efficiency.

Gross Margin53.63
Operating Margin12.40
Pretax Margin17.23
Profit Margin13.10
EBITDA Margin12.40

Scores

Lincoln Pharmaceuticals Limited posts an Altman Z-Score of 6.81, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score6.81